PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Targeting the programmed death-1 pathway in lymphoid neoplasms.

Abstract Programmed death-1 (PD-1) is a co-inhibitory molecule and is seen in CD4+ and CD8+ T cells. Upon binding to its ligands, programmed death ligand-1 (PD-L1) and -2 (PD-L2), PD-1 negatively regulates interleukin 2 (IL-2) production and T cell proliferation. Activated effector T-cells, which kill cancer cells, can be affected by PD-1 signaling in some lymphoid neoplasm that express PD-L1 or PD-L2. PD-L1 expression in tumor cells can be induced by extrinsic signal (i.e. interferon gamma) or intrinsic signals, such as genetic aberrations involving 9p24.1, latent Epstein-Barr virus infection, PD-L1 3'- untranslated region disruptions, and activated Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway. Anti-PD-1 therapy improves the overall response rate to treatment in patients with lymphoid neoplasms, particularly relapsed/refractory classical Hodgkin lymphoma. Inspired by their success in treating patients with classical Hodgkin lymphoma, medical practitioners have expanded PD-1 therapy, given as a single therapy or in combination with other drugs, to patients with other types of lymphoma. In this review, current clinical trials with anti-PD-1 or anti-PD-L1 drugs are summarized. The results of numerous clinical trials will broaden our understanding of PD-1 pathway and shall expand the list of patients who will get benefit from these agents including those who suffer from lymphoid neoplasms.
PMID
Related Publications

Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy.

Checkpoint Inhibition: Programmed Cell Death 1 and Programmed Cell Death 1 Ligand Inhibitors in Hodgkin Lymphoma.

Human brain endothelial cells endeavor to immunoregulate CD8 T cells via PD-1 ligand expression in multiple sclerosis.

Structure and interactions of the human programmed cell death 1 receptor.

Targeting immune checkpoints in lymphoma.

Authors

Mayor MeshTerms
Keywords

Immune checkpoint

Lymphoid neoplasms

PD-1

PD-L1

PD-L2

Journal Title cancer treatment reviews
Publication Year Start




PMID- 28242522
OWN - NLM
STAT- MEDLINE
DA  - 20170228
DCOM- 20170314
LR  - 20170314
IS  - 1532-1967 (Electronic)
IS  - 0305-7372 (Linking)
VI  - 54
DP  - 2017 Mar
TI  - Targeting the programmed death-1 pathway in lymphoid neoplasms.
PG  - 99-109
LID - S0305-7372(17)30018-X [pii]
LID - 10.1016/j.ctrv.2017.01.009 [doi]
AB  - Programmed death-1 (PD-1) is a co-inhibitory molecule and is seen in CD4+ and
      CD8+ T cells. Upon binding to its ligands, programmed death ligand-1 (PD-L1) and 
      -2 (PD-L2), PD-1 negatively regulates interleukin 2 (IL-2) production and T cell 
      proliferation. Activated effector T-cells, which kill cancer cells, can be
      affected by PD-1 signaling in some lymphoid neoplasm that express PD-L1 or PD-L2.
      PD-L1 expression in tumor cells can be induced by extrinsic signal (i.e.
      interferon gamma) or intrinsic signals, such as genetic aberrations involving
      9p24.1, latent Epstein-Barr virus infection, PD-L1 3'- untranslated region
      disruptions, and activated Janus kinase/signal transducer and activator of
      transcription (JAK/STAT) pathway. Anti-PD-1 therapy improves the overall response
      rate to treatment in patients with lymphoid neoplasms, particularly
      relapsed/refractory classical Hodgkin lymphoma. Inspired by their success in
      treating patients with classical Hodgkin lymphoma, medical practitioners have
      expanded PD-1 therapy, given as a single therapy or in combination with other
      drugs, to patients with other types of lymphoma. In this review, current clinical
      trials with anti-PD-1 or anti-PD-L1 drugs are summarized. The results of numerous
      clinical trials will broaden our understanding of PD-1 pathway and shall expand
      the list of patients who will get benefit from these agents including those who
      suffer from lymphoid neoplasms.
CI  - Copyright (c) 2017 Elsevier Ltd. All rights reserved.
FAU - Ok, Chi Young
AU  - Ok CY
AD  - The Department of Hematopathology, The University of Texas MD Anderson Cancer
      Center, Houston, TX, USA. Electronic address: COk@mdanderson.org.
FAU - Young, Ken H
AU  - Young KH
AD  - The Department of Hematopathology, The University of Texas MD Anderson Cancer
      Center, Houston, TX, USA. Electronic address: khyoung@mdanderson.org.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20170211
PL  - Netherlands
TA  - Cancer Treat Rev
JT  - Cancer treatment reviews
JID - 7502030
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antigens, CD274)
RN  - 0 (CD274 protein, human)
RN  - 0 (PDCD1 protein, human)
RN  - 0 (PDCD1LG2 protein, human)
RN  - 0 (Programmed Cell Death 1 Ligand 2 Protein)
RN  - 0 (Programmed Cell Death 1 Receptor)
SB  - IM
MH  - Antibodies, Monoclonal/*pharmacology
MH  - Antigens, CD274/chemistry/genetics/metabolism
MH  - Humans
MH  - Lymphoma/*drug therapy/*pathology
MH  - Molecular Targeted Therapy/*methods
MH  - Programmed Cell Death 1 Ligand 2 Protein/chemistry/genetics/metabolism
MH  - Programmed Cell Death 1 Receptor/chemistry/genetics/metabolism
MH  - T-Lymphocytes/drug effects/pathology
OTO - NOTNLM
OT  - Immune checkpoint
OT  - Lymphoid neoplasms
OT  - PD-1
OT  - PD-L1
OT  - PD-L2
EDAT- 2017/03/01 06:00
MHDA- 2017/03/16 06:00
CRDT- 2017/03/01 06:00
PHST- 2016/09/24 [received]
PHST- 2017/01/23 [revised]
PHST- 2017/01/29 [accepted]
AID - S0305-7372(17)30018-X [pii]
AID - 10.1016/j.ctrv.2017.01.009 [doi]
PST - ppublish
SO  - Cancer Treat Rev. 2017 Mar;54:99-109. doi: 10.1016/j.ctrv.2017.01.009. Epub 2017 
      Feb 11.

<?xml version="1.0" encoding="UTF-8"?>
<b:Sources SelectedStyle="" xmlns:b="http://schemas.openxmlformats.org/officeDocument/2006/bibliography"  xmlns="http://schemas.openxmlformats.org/officeDocument/2006/bibliography" >
</b:Sources>